²é¿´: 1460  |  »Ø¸´: 4
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

xingchen7_

½ð³æ (СÓÐÃûÆø)

[½»Á÷] ¸¡Ã×ÿÖÜרÀû¿ìѶ£º2014Äê3Ô£¨Ò»£©ÒÑÓÐ4È˲ÎÓë

1. WO 2014023258

±êÌâ: Pyrazole carboxamide compounds, compositions and methods of use

ÉêÇëÈË: ÂÞÊÏ£»»ùÒòÌ©¿Ë

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 682063£»2013 US 764930£»2013 US 764434

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:

ÊÊÓ¦Ö¢: Ñ×Ö¢

רÀûÕªÒª: Provided herein are compounds of formula (AA): N N H HN O N N R R 6 A (R a ) p, (AA) stereoisomers or a pharmaceutically acceptable salt thereof, wherein A, R a, p, R and R 6 are defined herein, compositions including the compounds and methods of manufacturing and using the compounds for the treatment of diseases.

±¸×¢: ITK (EMT) ¼¤Ã¸ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆÑ×Ö¢¡£Ò»¸öʾÀýÐÔ»¯ºÏÎï¶ÔITKµÄ»îÐÔΪKiСÓÚ0.1 nM.



2. WO 2014025854

±êÌâ: Piperidine amide derivatives as HIV attachment inhibitors

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 681306

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:201403060102

ÊÊÓ¦Ö¢: HIV¸ÐȾ

רÀûÕªÒª: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formule (I): wherein A is selected from the group consisting of:formule (II) and wherein Z is selected from the group consisting of: formule (III):,, and. are useful as HIV attachment inhibitors.

±¸×¢: HIV Õ³¸½ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆHIV¸ÐȾ¡£Ò»¸öʾÀýÐԵĻ¯ºÏÎïÔÚMT-2ϸ°ûÖжÔHIV-1µÄ»îÐÔΪEC50=0.20 nM¡£



3. WO 2014023815

±êÌâ: New antibacterial compounds

ÉêÇëÈË: ÑîÉ­

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 180103

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:201403060103

ÊÊÓ¦Ö¢: ϸ¾ú¸ÐȾ

רÀûÕªÒª: The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

±¸×¢: Ï©õ£»ù ¨C £¨õ£»ùÔØÌåµ°°×£©»¹Ô­Ã¸FablÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆϸ¾ú¸ÐȾ¡£Ò»¸öʾÀýÐÔ»¯ºÏÎï¿ÉÒÔÒÖÖƽð»ÆÉ«ÆÏÌÑÇò¾úATCC 29213 Fabl£¬ÆäIC50´ïµ½0.407356 mcg/ml¡£



4. WO 2014024119

±êÌâ: Heterocyclic amides as ITK inhibitors

ÉêÇëÈË: ¸ñÂ×Âí¿Ë

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 IN 2888£»2012 IN 2257£»2013 IN 762£»2012 US 717224£»2012 US 696439

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:201403060104

ÊÊÓ¦Ö¢: Ïø´­£»ÂýÐÔ×èÈûÐԷβ¡£»ÌØÒìÐÔƤÑ×£»Àà·çʪÐԹؽÚÑ×£»¹ýÃôÐÔ±ÇÑ×

רÀûÕªÒª: The present invention is directed to heterocyclic amide compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by ITK.

±¸×¢: ITK (EMT)ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆÏø´­¡¢ÂýÐÔ×èÈûÐԷμ²²¡¡¢Æ¤Ñס¢Àà·çʪÐԹؽÚÑס¢¹ýÃôÐÔ±ÇÑס¢¶à·¢ÐÔÓ²»¯Ö¢¡¢ÌÛÍ´µÈ¼²²¡¡£±¾×¨ÀûÖеÄÌṩµÄ²¿·ÖʾÀý»¯ºÏÎïIC50СÓÚ50 nM ¡£



5. WO 2014023367

±êÌâ: Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORgamma

ÉêÇëÈË: Phenex Pharmaceuticals AG

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 681296£»2012 EP 5789

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:201403060105

ÊÊÓ¦Ö¢: ¼¡Î®Ëõ²àË÷Ó²»¯Ö¢£»Ïø´­£»IÐÍÌÇÄò²¡£»³¦Ñ×£»¶à·¢ÐÔÓ²»¯Ö¢£»Òøм²¡£»Àà·çʪÐԹؽÚÑ×£»¼¹ÖùÑ×

רÀûÕªÒª: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

±¸×¢: ROR gamma ÊÜÌåµ÷¿Ø¼Á¿ÉÒÔÓÃÓÚÖÎÁÆÑ×Ö¢¡¢×ÔÉíÃâÒߣ¬È缡ήËõÐÔ¼¹ËèâüË÷Ó²»¯Ö¢¡¢¶à·¢ÐÔÓ²»¯Ö¢¡¢Å£Æ¤Ñ¢¡¢Àà·çʪÐԹؽÚÑס¢¹ýÃôÐÔʪÕîµÈ¡£Ò»¸öʾÀýÐԵĻ¯ºÏÎïÔÚBL-21ϸ°ûÖÐÏÔʾÒÖÖÆRORgammaµÄ»îÐÔΪpIC50Ϊ6.3nM¡£



6. WO 2014023385

±êÌâ: Pyridopyrimidine derivatives as protein kinase inhibitors

ÉêÇëÈË: Ĭ¿Ë

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 5716

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:201403060106

ÊÊÓ¦Ö¢: Ïø´­£»Ö×Áö£»¶à·¢ÐÔÓ²»¯Ö¢£»Àà·çʪÐԹؽÚÑ×£»ºì°ßÀÇ´¯

רÀûÕªÒª: Compounds of the formula (I) in which R, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

±¸×¢: Syk¼¤Ã¸ÒÖÖƼÁ¿ÉÒÔÓÃÓÚ¶àÖÖ¼²²¡µÄÖÎÁÆ£¬ÈçÖ×Áö¡¢Àà·çʪÐԹؽÚÑס¢ºì°ßÀÇ´¯¡¢Ïø´­¡¢¶à·¢ÐÔÓ²»¯Ö¢¡¢ÌÇÄò²¡¡¢ÌÆÊÏ×ÛºÏÖ¢µÈ¡£Ò»¸öʾÀýÐÔ»¯ºÏÎï¶ÔSykµÄÒÖÖÆ»îÐÔΪIC500.1 mcM ¡£



7. WO 2014023673£»US 2014044674

±êÌâ: Interleukin-10 fusion proteins and uses thereof

ÉêÇëÈË: ÂÞÊÏ

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 179709

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: Èںϵ°°×

ÊÊÓ¦Ö¢: Ñ×Ö¢£»³¦Ñ×£»Àà·çʪÐԹؽÚÑ×

רÀûÕªÒª: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

±¸×¢: ÓÉIgGÀ࿹ÌåºÍIL-10·Ö×Ó×é³ÉµÄÈںϵ°°×¿ÉÒÔÓÃÓÚÑ×Ö¢µÄÖÎÁÆ»òÔ¤·À£¬ÌرðÊÇÑ×Ö¢ÐÔ³¦¼²²¡ºÍÀà·çʪ¹Ø½ÚÑ×µÄÖÎÁÆ¡£Ò»¸öʾÀýÐÔµÄÈںϵ°°×¿ÉÒÔ°ÐÏòÈËÔ´FAP¡£¸ÃÈںϵ°°×¿ÉÒÔÒÖÖÆLPSÓÕµ¼µÄÇ°Ñ×ÐÔϸ°û»îËØ£¨IL-6, IL-1betaºÍTNF-alpha£©µÄ²úÎÆäEC50·Ö±ðΪ0.054, 0.049ºÍ0.017 nM¡£



8. WO 2014023674

±êÌâ: Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

ÉêÇëÈË: ÂÞÊÏ

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 179381

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:201403060108

ÊÊÓ¦Ö¢: ½¹ÂÇ£»°¢¶û×Ⱥ£Ä¬£»ÒÖÓô£»Öзç

רÀûÕªÒª: The present invention relates to compounds of general formula (I), wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, lower alkyl or lower alkyl substituted by halogen; R3 is phenyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuran-5-yl or a 5- and 6-membered heteroaryl, wherein phenyl and the 5- and 6-membered heteroaryl groups may be substituted by one or more substituents, selected from cyano, nitro, amino and lower di-alkylamino, lower alkyl sulfonyl, lower alkoxy, lower alkoxy substituted by halogen, halogen, lower alkyl, lower alkyl substituted by halogen or lower alkyl substituted by hydroxyl; X is -CH(lower alkyl)-, -CH2-, -CH2CH2- or �CH(lower alkyl)CH2-; R is hydrogen or lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson¡¯s disease, dementia, Alzheimer¡¯s disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington¡¯s disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

±¸×¢: Éñ¾­ÏµÍ³µ÷½ÚÀ໯ºÏÎï¿ÉÒÔÓÃÓÚÖÎÁƽ¹ÂÇ¡¢°¢¶û×Ⱥ£Ä¬¡¢ÒÖÓôºÍÖзçµÈ¼²²¡¡£Ò»¸öʾÀýÐԵĻ¯ºÏÎïµÄEC150=0.002 mcM¡£



9. WO 2014026054

±êÌâ: CD20 scFv-ELPs methods and therapeutics

ÉêÇëÈË: University of Southern California (USC)

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 682029

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: Èںϵ°°×

ÊÊÓ¦Ö¢: ×ÔÉíÃâÒߣ»Ö×Áö

רÀûÕªÒª: Disclosed herein are recombinant polypeptides comprising an elastin-like peptide (ELP) and a scFv, or a biological equivalent of the scFv. Also disclosed are compositions containing scFv-ELP polypeptides and methods of use.

±¸×¢: °üº¬µ¯ÐÔµ°°×ÑùëÄ£¨ELP£©Èںϵ¥Á´¿¹Ì壨scFv£©µÄÖØ×é¶àëÄ¿ÉÒÔÓÃÓÚÖÎÁÆ°©Ö¢ºÍ×ÔÉíÃâÒßÀ༲²¡¡£Ò»¸öÓÉÀûÍ×Îôµ¥¿¹ÑÜÉúµÄ¿¹CD20µÄscFvµ¥Á´¿¹ÌåÈÚºÏELP(A-192)µÄÈںϵ°°×scFv-ELPs¿ÉÒÔÑÓ»ºÖ×ÁöÉú³¤²¢ÑÓ³¤Éú´æÆÚ¡£



10. WO 2014023814

±êÌâ: New antibacterial compounds

ÉêÇëÈË: ÑîÉ­

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 180100

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601010

ÊÊÓ¦Ö¢: ϸ¾ú¸ÐȾ

רÀûÕªÒª: The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

±¸×¢: Ï©õ£»ù ¨C £¨õ£»ùÔØÌåµ°°×£©»¹Ô­Ã¸FablÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆϸ¾ú¸ÐȾ¡£Ò»¸öʾÀýÐÔ»¯ºÏÎï¿ÉÒÔÒÖÖƽð»ÆÉ«ÆÏÌÑÇò¾úATCC 29213 Fabl£¬ÆäIC50´ïµ½0.27 mcg/ml¡£´ËÍâÆäÒ²¶ÔS. aureus ATCC 29213 and S. aureus ATCC 29213¾ßÓлîÐÔ£¬·Ö±ðΪIC90 = 0.24 ºÍ0.21 mcg/ml¡£



11. WO 2014025708

±êÌâ: Compounds that are S1P modulating agents and/or ATX modulating agents

ÉêÇëÈË: Biogen Idec Inc.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 679984

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601011

ÊÊÓ¦Ö¢: ¶à·¢ÐÔÓ²»¯Ö¢£»ÌÛÍ´£»Àà·çʪÐԹؽÚÑ×

רÀûÕªÒª: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

±¸×¢: ENPP2ÒÖÖƼÁ»òSIPµ÷½Ú¼Á¿ÉÓÃÓÚÀà·çʪÐԹؽÚÑ׹ؽÚÑס¢¶à·¢ÐÔÓ²»¯Ö¢ºÍÌÛÍ´¡¢Ö×Áö¡¢ÃâÒߵȼ²²¡µÄÖÎÁÆ¡£ ʾÀýÐÔ»¯ºÏÎï¶ÔENPP2µÄIC50СÓÚ0.5 mcM¡£



12. WO 2014025709

±êÌâ: Compounds that are S1P modulating agents and/or ATX modulating agents

ÉêÇëÈË: Biogen Idec Inc.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 679992

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601012

ÊÊÓ¦Ö¢: ¶à·¢ÐÔÓ²»¯Ö¢£»ÌÛÍ´£»Àà·çʪÐԹؽÚÑ×

רÀûÕªÒª: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

±¸×¢: ENPP2ÒÖÖƼÁ»òSIPµ÷½Ú¼Á¿ÉÓÃÓÚÀà·çʪÐԹؽÚÑ׹ؽÚÑס¢¶à·¢ÐÔÓ²»¯Ö¢ºÍÌÛÍ´¡¢Ö×Áö¡¢ÃâÒߵȼ²²¡µÄÖÎÁÆ¡£ ʾÀýÐÔ»¯ºÏÎï¶ÔENPP2µÄIC50СÓÚ0.5 mcM¡£



13. WO 2014025850

±êÌâ: Tricyclic amidine derivatives as HIV attachment inhibitors

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 681336

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601013

ÊÊÓ¦Ö¢: HIV¸ÐȾ

רÀûÕªÒª: Compounds of Formula I, including pharmaceutically acceptable salts thereof: (F) wherein A is selected from the group consisting of: (F) and;(F) and wherein Z is: (F) are useful as HIV attachment inhibitors.

±¸×¢: HIV Õ³¸½ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆHIV¸ÐȾ¡£Ò»¸öʾÀýÐԵĻ¯ºÏÎïÔÚMT-2ϸ°ûÖжÔHIV-1µÄ»îÐÔΪEC50=1.83nM¡£



14. WO 2014025852

±êÌâ: Tricyclic alkene derivatives as HIV attachment inhibitors

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 681329

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601014

ÊÊÓ¦Ö¢: HIV¸ÐȾ

רÀûÕªÒª: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.

±¸×¢: HIV Õ³¸½ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆHIV¸ÐȾ¡£Ò»¸öʾÀýÐԵĻ¯ºÏÎïÔÚMT-2ϸ°ûÖжÔHIV-1µÄ»îÐÔΪEC50=0.28 nM¡£



15. WO 2014022936

±êÌâ: Chlamydia antigen compositions and uses thereof

ÉêÇëÈË: University of British Columbia

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 680836

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: Èںϵ°°×

ÊÊÓ¦Ö¢: ÒÂÔ­Ìå¸ÐȾ

רÀûÕªÒª: The present invention provides in part fusion proteins derived from Chlamydia spp. The present invention also provides in part methods for treating or preventing Chlamydia infection using the fusion proteins.

±¸×¢: ÃâÒß×éºÏÎïÀàµÄÈںϵ°°×¿ÉÒÔ×÷ΪÒßÃ磬ÓÃÓÚÒÂÔ­Ìå¸ÐȾµÄÔ¤·ÀºÍÖÎÁÆ¡£±¾×¨ÀûÖУ¬Èںϵ°°× Chlamydia¿¹ÌåչʾÁËÁ¼ºÃÁË¿¹ÒÂÔ­Ìå¸ÐȾ»îÐÔ¡£



16. WO 2014022767

±êÌâ: Dihydropyridone P1 as factor XIa inhibitors

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2013 US 787081£»2012 US 679197

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601016

ÊÊÓ¦Ö¢: Ѫ˨

רÀûÕªÒª: The present invention provides compounds of Formula (X)Formula(X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

±¸×¢: ÄýѪÒò×ÓXIaºÍ/»ò¼¤ëÄÊÍ·ÅøB£¨Ñª½¬¼¤ëÄÊÍ·Åø; KLKB1£©¿ÉÒÔÓÃÓÚÖÎÁÆѪ˨¡£ÑªË¨Ë¨ÈûÐÔ²¡Ö¢Èç²»Îȶ¨ÐÍÐĽÊÍ´£¬¼±ÐÔ¹Ú×´¶¯Âö×ÛºÏÕ÷£¬ÐÄ·¿ÏËάÐÔ²ü¶¯£¬Ðļ¡¹£Èû£¬¶ÌÔÝÐÔȱѪ·¢×÷£¬Öз磬¶¯ÂöÖàÑùÓ²»¯£¬ÍâÖÜ×èÈûµÄÖÎÁÆÓÐÓõÄÒÖÖƼÁ¶¯Âö¼²²¡£¬¾²ÂöѪ˨Ðγɣ¬ÄÔ¶¯ÂöѪ˨Ðγɣ¬ÄÔ£¬ÉöºÍ·Î˨ÈûµÈ¡£±¾×¨ÀûÖеĵÄʾÀý»¯ºÏÎï¶ÔÄýѪÒò×ÓXIaºÍKLKB1µÄ KiÖµ·Ö±ðΪ 0.05ºÍ 0.56 nM¡£



17. WO 2014022766£»US 2014038969

±êÌâ: Dihydropyridone P1 as factor XIa inhibitors

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2013 US 957609£»2012 US 679197£»2013 US 786992

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601017

ÊÊÓ¦Ö¢: Ѫ˨

רÀûÕªÒª: The present invention provides compounds of Formula (VIII): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

±¸×¢: ÄýѪÒò×ÓXIaºÍ/»ò¼¤ëÄÊÍ·ÅøB£¨Ñª½¬¼¤ëÄÊÍ·Åø; KLKB1£©¿ÉÒÔÓÃÓÚÖÎÁÆѪ˨¡£ÑªË¨Ë¨ÈûÐÔ²¡Ö¢Èç²»Îȶ¨ÐÍÐĽÊÍ´£¬¼±ÐÔ¹Ú×´¶¯Âö×ÛºÏÕ÷£¬ÐÄ·¿ÏËάÐÔ²ü¶¯£¬Ðļ¡¹£Èû£¬¶ÌÔÝÐÔȱѪ·¢×÷£¬Öз磬¶¯ÂöÖàÑùÓ²»¯£¬ÍâÖÜ×èÈûµÄÖÎÁÆÓÐÓõÄÒÖÖƼÁ¶¯Âö¼²²¡£¬¾²ÂöѪ˨Ðγɣ¬ÄÔ¶¯ÂöѪ˨Ðγɣ¬ÄÔ£¬ÉöºÍ·Î˨ÈûµÈ¡£±¾×¨ÀûÖеĵÄʾÀý»¯ºÏÎï¶ÔÄýѪÒò×ÓXIaºÍKLKB1µÄ KiÖµ·Ö±ðΪ 0.25ºÍ 0.7 nM¡£



18. WO 2014022752

±êÌâ: Macrocycles as Pim inhibitors

ÉêÇëÈË: °²½ø

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 679521

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601018

ÊÊÓ¦Ö¢: Ö×Áö

רÀûÕªÒª: The invention relates to compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

±¸×¢: Pim¼¤Ã¸¿ÉÒÔÓÃÓÚÖÎÁÆÖ×Áö¡£Pim·ÖΪPim1¡¢Pim2¡¢Pim3µÈÈýÖÖÑÇÐÍ¡£ ±¾×¨ÀûµÄ»¯ºÏÎï¶Ô Pim-1, Pim-2, Pim-1-Mn and Pim-2-MnµÄ»îÐÔ·Ö±ðΪIC50 = 0.000209¡¢0.000286¡¢0.0000498ºÍ0.0000634 mcM¡£



19. WO 2014022744

±êÌâ: Indole-substituted pyrrolopyrimidinyl inhibitors of Uba6

ÉêÇëÈË: Millennium Pharmaceuticals, Inc.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 679109

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601019

ÊÊÓ¦Ö¢: Ö×Áö

רÀûÕªÒª: Disclosed are chemical entities that inhibit Uba6, each of which is a compound of Formula /: Formula (I) or a pharmaceutically acceptable salt thereof, wherein R*1 is -H or -CH3; and Y is Formula (II) or Formula (III), wherein R2 is -H, -CH3 or C1-4 alkyloxycarbonyl; and RS7.1, RS7.2 and RS8.1 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.

±¸×¢: UBA6øÒÖÖƼÁ¿ÉÒÔÓÃÓëÖÎÁÆÖ×Áö¼²²¡¡£Ò»¸öʾÀýÐÔ»¯ºÏÎï¶ÔÈËÔ´ÖØ×éhis-UBA6øµÄIC50СÓÚ50nM¡£



20. EP 2692357£»WO 2014020062

±êÌâ: Novel anti-Plasmodium parasite antibodies

ÉêÇëÈË: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung eV

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 679380£»2012 EP 179315

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: ¿¹Ìå

ÊÊÓ¦Ö¢: Õï¶Ï£»Å±¼²

רÀûÕªÒª: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

±¸×¢: ÈË¿¹Ìå»òÆ俹ԭ¿ÉÒÔÌØÒìÐԵĽáºÏMSP10£¬ÇÒ¿ÉÒÔÓÃÓÚű¼²µÄÕï¶ÏºÍÖÎÁÆ¡£±¾×¨ÀûÖÐÁоٵÄÈ˵¥¿Ë¡IgG1 kappa¿¹ÌåչʾÁ˶ÔEGF Óò1µÄÌØÒìÐÔÇ׺ÍÁ¦¡£



21. WO 2014022343

±êÌâ: 7-Hydroxy-indolinyl antagonists of P2Y1 receptor

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 678151

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601021

ÊÊÓ¦Ö¢: Ѫ˨

רÀûÕªÒª: The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.

±¸×¢: P2Y1ÊÜÌåÞ׿¹¼Á¿ÉÒÔÓÃÓÚÖÎÁÆѪ˨¡£±¾×¨ÀûÖÐÁоٵĻ¯ºÏÎïÔÚHEK-293ϸ°ûÖУ¬Ki=11.3nM¡£



22. WO 2014022253

±êÌâ: Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor

ÉêÇëÈË: °ÙʱÃÀÊ©¹ó±¦

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 678190

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601022

ÊÊÓ¦Ö¢: Ѫ˨

רÀûÕªÒª: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used as medicaments.

±¸×¢: P2Y1ÊÜÌåÞ׿¹¼Á¿ÉÒÔÓÃÓÚÖÎÁÆѪ˨¡£±¾×¨ÀûÖÐÁоٵĻ¯ºÏÎïÔÚHEK-293ϸ°ûÖУ¬Ki=16 nM¡£



23. WO 2014021281

±êÌâ: Partially saturated nitrogen-containing heterocyclic compound

ÉêÇëÈË: Taisho Pharmaceutical Co., Ltd.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 JP 168828

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601023

ÊÊÓ¦Ö¢: ƶѪ

רÀûÕªÒª: Provided is a compound which is represented by general formula (I¡¯) and has an excellent PHD2-inhibiting activity or a pharmaceutically acceptable salt thereof. (In the general formula (I¡¯), W, Y, R2, R3, R4 and Y4 are as defined in the description.)

±¸×¢: ȱÑõÓÕµ¼Òò×Ó£¨HIF£©¸¬°±õ£ôÇ»¯Ã¸2£¨PHD2£©ÒÖÖƼÁ¶ÔƶѪ֢µÄÖÎÁÆÓÐЧ¡£±¾×¨ÀûÖеĻ¯ºÏÎïÔÚ293FTϸ°ûÖпÉÒÔÒÖÖÆPHD2£¬ÆäIC50=14 nM¡£



24. WO 2014020350

±êÌâ: PAR2 receptor antagonists

ÉêÇëÈË: Proximagen Ltd.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 GB 13700£»2013 GB 52069

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601024

ÊÊÓ¦Ö¢: Ñ×Ö¢£»Ö×Áö£»ÌØÒìÐÔƤÑ×£»³¦Ñ×£»³¦Ò××ÛºÏÕ÷£»ÌÛÍ´£»Òøм²¡

רÀûÕªÒª: Compounds of formula (I) or pharmaceutically acceptable salts, solvates or hydrates thereof wherein P, Q, X, Y, R1, R2, R3, R10, R11, and R12 are as defined in the claims, and the use those compounds in medicine.

±¸×¢: PAR2Þ׿¹¼Á¿ÉÒÔÓÃÓÚÖÎÁÆÑ×Ö¢¡¢Ö×Áö¡¢ÌÛÍ´¡¢Òøм²¡µÈ¼²²¡¡£±¾×¨ÀûÖеÄʾÀý»¯ºÏÎï¶ÔPAR2µÄIC500.1 mcM¡£



25. WO 2014022728£»US 2014038952

±êÌâ: Substituted 5-(quinazolin-2-yl)pyrimidin-2-amine derivatives useful as PI3K/mTOR inhibitors for the treatment of cancer

ÉêÇëÈË: Endo Pharmaceuticals Inc.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2013 US 957470£»2012 US 678694

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601025

ÊÊÓ¦Ö¢: Ö×Áö£»Ñ×Ö¢

רÀûÕªÒª: The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds of formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

±¸×¢: PI3Kalpha/mTOR(FRAP1)ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆÑ×Ö¢ºÍÖ×Áö¡£ ±¾×¨ÀûÖеĻ¯ºÏÎïÔÚH1047R¡¢E545K ºÍmTORµÄIC50¾ùСÓÚ50 nM£¬¶Ô PI3K beta and gammaµÄIC50¾ùСÓÚ500 nM£¬¶ÔPI3KdeltaµÄIC50 1mcM¡£



26. US 2014045856£»US 2014045857£»WO 2014019979

±êÌâ: 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

ÉêÇëÈË: ²ªÁÖ¸ñÒó¸ñº²

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 178713

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601026

ÊÊÓ¦Ö¢: °¢¶û×Ⱥ£Ä¬£»¼ÇÒäȱÏÝ

רÀûÕªÒª: The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

±¸×¢: PDE2AºÍ/»òPDE10AÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆ°¢¶û×Ⱥ£Ä¬ºÍ¼ÇÒäȱÏݵȾ«ÉñÀ༲²¡¡£±¾×¨ÀûÖеÄÒ»¸öʾÀýÐÔ»¯ºÏÎï·Ö±ðÔÚ¶ÔPDE2AµÄIC50 = 0.071mcM£¬¶ÔPD10AµÄIC50 = 3.01mcM¡£



27. WO 2014019908

±êÌâ: Substituted pyrroles active as kinases inhibitors

ÉêÇëÈË: Nerviano Medical Sciences Srl

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 178946

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601027

ÊÊÓ¦Ö¢: ¶¯ÂöÖàÑùÓ²»¯£»Ö×Áö£»ÃâÒߣ»HIV¸ÐȾ£»Éñ¾­ÍËÐм²²¡£»Ç°ÁÐÏÙÔöÉú£»Òøм²¡£»Öзç

רÀûÕªÒª: The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

±¸×¢: Janus ¼¤Ã¸ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆÖ×Áö¡¢¶¯ÂöÖàÑùÓ²»¯¡¢ÃâÒߵȶàÖÖ¼²²¡¡£±¾×¨ÀûÖÐÌṩµÄʾÀý»¯ºÏÎï¶ÔJak1, Jak2 ºÍ Tyk2 µÄ IC50¾ùΪ0.001 mcM¡£



28. WO 2014019023

±êÌâ: alpha7 Nicotinic acetylcholine receptor modulators and uses thereof-I

ÉêÇëÈË: Bionomics Ltd.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 AU 903296£»2013 AU 900167

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601028

ÊÊÓ¦Ö¢: ÈÏÖªÕÏ°­£»Ñ×Ö¢£»Éñ¾­ÍËÐÐÐÔ¼²²¡£»Éñ¾­ÌÛÍ´

רÀûÕªÒª: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (a7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of a7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.

±¸×¢: alpha7 Ñ̼îÒÒõ£µ¨¼îÊÜÌ壨nAChRµÄ£©µÄµ÷½Ú¼Á¿É×÷ΪÑ×Ö¢¡¢ÈÏÖªÕÏ°­¡¢Éñ¾­ÌÛÍ´µÈ¼²²¡µÄÖÎÁÆÓÃ;¡£±¾×¨ÀûÌṩµÄʾÀý»¯ºÏÎï¶ÔÓÚ alpha7ÊÜÌå¾ßÓкܺõĻîÐÔ¡£



29. WO 2014018887

±êÌâ: ATX modulating agents

ÉêÇëÈË: Biogen Idec Inc.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 676698

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601029

ÊÊÓ¦Ö¢: ¶à·¢ÐÔÓ²»¯Ö¢£»ÂýÐÔÌÛÍ´£»Àà·çʪÐԹؽÚÑ×

רÀûÕªÒª: Compounds of formula (I) can modulate the activity of autotaxin (ATX).

±¸×¢: ENPP2ÒÖÖƼÁ»òSIPµ÷½Ú¼Á¿ÉÓÃÓÚÀà·çʪÐԹؽÚÑ׹ؽÚÑס¢¶à·¢ÐÔÓ²»¯Ö¢ºÍÌÛÍ´¡¢Ö×Áö¡¢ÃâÒߵȼ²²¡µÄÖÎÁÆ¡£ ʾÀýÐÔ»¯ºÏÎï¶ÔENPP2µÄIC50СÓÚ100 nM¡£



30. WO 2014018881

±êÌâ: ATX modulating agents

ÉêÇëÈË: Biogen Idec Inc.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 676705

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601030

ÊÊÓ¦Ö¢: ¶à·¢ÐÔÓ²»¯Ö¢£»ÂýÐÔÌÛÍ´£»Àà·çʪÐԹؽÚÑ×

רÀûÕªÒª: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

±¸×¢: ENPP2ÒÖÖƼÁ»òSIPµ÷½Ú¼Á¿ÉÓÃÓÚÀà·çʪÐԹؽÚÑ׹ؽÚÑס¢¶à·¢ÐÔÓ²»¯Ö¢ºÍÌÛÍ´¡¢Ö×Áö¡¢ÃâÒߵȼ²²¡µÄÖÎÁÆ¡£ ʾÀýÐÔ»¯ºÏÎï¶ÔENPP2µÄIC50СÓÚ100 nM¡£



31. WO 2014018919

±êÌâ: Seriniquinones, melanoma-specific anticancer agents

ÉêÇëÈË: University of California, Oakland

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 676427

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601031

ÊÊÓ¦Ö¢: Ö×Áö

רÀûÕªÒª: Accordingly, there are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.

±¸×¢: SeriniquinonesÑÜÉúÎï¿ÉÒÔ×÷ΪdermcidinÒÖÖƼÁͨ¹ýÓÕµ¼µòÍöµÄ»úÖÆÓÃÓÚÖ×Áö£¬ÓÈÆäÊǺÚÉ«ËØÁöºÍÇ°ÁÐÏÙ°©µÄÖÎÁÆ¡£±¾×¨ÀûÖеÄʾÀý»¯ºÏÎï¶Ô·ÇСϸ°û·Î°©Ï¸°û¡¢Éö°©¡¢Âѳ²°©¡¢Ç°ÁÐÏÙ°©¡¢ÈéÏÙ°©µÈϸ°ûµÄÒÖÖÆ»îÐÔ´ïµ½10 mcM¡£



32. WO 2014016300

±êÌâ: Glucagon analogues

ÉêÇëÈË: Zealand Pharma A/S

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 674706£»2013 DK 360£»2013 US 785611

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: ¶àëÄ

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601032

ÊÊÓ¦Ö¢: µÍѪÌÇ

רÀûÕªÒª: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

±¸×¢: GCGRÊÜÌ弤¶¯¼Á¿ÉÒÔÓÃÓÚµÍѪÌÇ¡¢·ÊÅÖ¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ¼²²¡µÄÖÎÁÆ¡£±¾×¨ÀûÖеÄʾÀý»¯ºÏÎï¶ÔÈËÔ´GCGRµÄEC50 = 0.15 nM¡£



33. EP 2689786£»WO 2014016312

±êÌâ: HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders

ÉêÇëÈË: Genticel SA

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 EP 305898

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: ÒßÃç

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:

ÊÊÓ¦Ö¢: ÈéÍ·×´Áö²¡¶¾¸ÐȾ

רÀûÕªÒª: The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide comprising antigens originating from different HPVs, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.

±¸×¢: ÓÐE7µ°°×ÑÜÉúÎï×é³ÉµÄ¶àëÄ¿ÉÒÔ×÷ΪÒßÃ磬ÓÃÓÚHPV¸ÐȾµÄÖÎÁÆ¡£±¾×¨ÀûÌṩÁ˶ÔHPV¸ÐȾÓÐЧµÄÒßÃç¡£



34. FR 2993562;WO 2014016507

±êÌâ: Novel selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions

ÉêÇëÈË: Galderma Research & Development, SNC

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 FR 57128

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: С·Ö×ÓÒ©Îï

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601034

ÊÊÓ¦Ö¢: Ƥ·ô²¡

רÀûÕªÒª: The present invention relates to novel compounds or to any of the salts thereof having the general formula (I), to the pharmaceutical and cosmetic compositions containing said compounds as well as to the use of said compounds and compositions for the treatment of diseases.

±¸×¢: ϸ°ûÉ«ËØ P450 CYP26A1ÒÖÖƼÁ¿ÉÒÔÓÃÓÚÖÎÁÆƤ·ôÀ༲²¡¡£±¾×¨ÀûÖеÄÒ»¸öʾÀý»¯ºÏÎï¶Ô CYP26A1µÄAC50 = 0.19 mcM£»¶ÔCYP26B1µÄAC50 = 50.33 mcM¡£



35. WO 2014016787

±êÌâ: Peptide-based compounds and uses thereof to treat beta-amyloid accumulation

ÉêÇëÈË: Pharma Bio, LLC.

ÓÅÏÈȨÈÕÆÚ¼°Ïà¹ØרÀû¹«¿ªºÅ: 2012 US 675205

Ïà¹ØºòÑ¡Ò©ÎïÀàÐÍ: ¶àëÄ

Ïà¹ØºòÑ¡Ò©Îﻯѧ½á¹¹:2014030601035

ÊÊÓ¦Ö¢: °¢¶û×Ⱥ£Ä¬

רÀûÕªÒª: The present application relates to novel peptide-based compounds, optionally comprising an immunoactive built-in adjuvant, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with ß- amyloid accumulation. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: [Ra-NP]m-Lp (I).

±¸×¢: ¿ÉÒÔÒÖÖƦÂ-µí·ÛÑùµ°°×µÄ¶àëÄ¿ÉÒÔÓÃ×÷°¢¶û×Ⱥ£Ä¬¡¢ÌÆÊÏ×ÛºÏÖ¢µÈ¼²²¡µÄÖÎÁÆ¡£±¾×¨ÀûÌṩÁ˾­ÐÞÊεÄÓÃÓÚÒÖÖƦÂ-µí·ÛÑùµ°°×µÄ¶àëĽṹ¡£
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌùר¼­ÍƼö

ÅÔÃÅ×óµÀ ¿¼ÑÐ×ÊÁÏ ÐÅÏ¢µ÷ÑРѧ¿ÆÍøÕ¾

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍƼö: (ÎÒÒ²ÒªÔÚÕâÀïÍƹã)

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍƼö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌøת ÎÒÒª¶©ÔÄÂ¥Ö÷ xingchen7_ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[ÂÛÎÄͶ¸å] ÎÒÔÚд¹ØÓÚ¶àά¿Õ¼äµÄÂÛÎÄ£¬Ï£ÍûÄÜÓë´ó¼Ò½»Á÷£¬×¼±¸ÔÚscienceÉÏ·¢±í +6 lgf519 2024-06-24 8/400 2024-06-26 08:24 by ÏþÄ»´Ô
[»ù½ðÉêÇë] Ìü¼¶ÏîÄ¿³öУȴûÖÐ +13 Iwould 2024-06-23 20/1000 2024-06-26 06:14 by foolishmani
[½Ìʦ֮¼Ò] ¸ßУ´ÇÖ°£¬ÒªÇóÅâ³¥£¬Õâµ½µ×ºÏ²»ºÏÀí +22 ´«¶¯_º£Éñ 2024-06-23 34/1700 2024-06-25 23:54 by Â×ÄɵÂmvp
[»ù½ðÉêÇë] ²©ºóÃæÉϵ½µ×ʲôʱºò³ö½á¹û£¿£¿£¿ +7 °®Ñ§lsy 2024-06-24 7/350 2024-06-25 19:24 by ±©×ßµÄËâÄà
[Óлú½»Á÷] ¶Ô±½ÒÒÏ©»Çõ£ÂȵĺϳɻúÀí 25+3 ¸ÃËÀµÄ¿ÆÑÐ 2024-06-24 5/250 2024-06-25 17:30 by Íõѧʿ
[»ù½ðÉêÇë] ½¹ÂÇûÓÐëÏßÓã¬Ä¬Ä¬Ç°ÐÐÊÇÍõµÀ£¡ +4 Ä®ÉÏÞ¼Ëó 2024-06-24 8/400 2024-06-25 14:32 by Ä®ÉÏÞ¼Ëó
[˶²©¼ÒÔ°] ÏÄÖÁ£¬Òª²»ÒªË¶²©ÁªÒê +4 ÎÒÊÇÍõС˧ 2024-06-21 6/300 2024-06-25 14:25 by ͥǰ»¨¿ªÔ¶ùÃ÷
[˶²©¼ÒÔ°] Êý¾Ý²»ºÃ +5 Hetai 2024-06-23 7/350 2024-06-25 12:37 by 1591099
[½Ìʦ֮¼Ò] ¸´µ©ÏÄͬѧÌá³ö¸ßУ³ÉÄêÈËѧÉúÍËѧ²»Ó¦¸ÃÈüҳ¤ÉóºË£¬´ó¼ÒÈÏͬÂ𣿠+10 ËÕ¶«Æ¶þÊÀ 2024-06-22 17/850 2024-06-24 16:52 by wanghuawei
[½ðÊô] EBSDµÄ½âÎöÂÊÖ»ÓÐ10% +3 wallace6666 2024-06-20 7/350 2024-06-24 16:52 by wallace6666
[»ù½ðÉêÇë] ¸Õ¸ÕÊÕµ½¿ÆÑÐÖ®ÓÑÓʼþ +28 olivermiaoer 2024-06-19 42/2100 2024-06-24 15:37 by jiann_li84
[´ß»¯] ÇóÖúԭλºìÍâ +3 jfdhj 2024-06-21 7/350 2024-06-24 10:52 by qvhm2609
[»ù½ðÉêÇë] ²©ºóÃæÉϺÍÌØÖú½ñÌì³öÂ𣿠+41 ¶ºÄúÍæ 2024-06-21 77/3850 2024-06-24 09:47 by weichuny
[ÂÛÎÄͶ¸å] OSAÆÚ¿¯Éó¸åÓâÆÚ +3 Thomas_Squid 2024-06-22 3/150 2024-06-23 15:20 by wspglt
[»ù½ðÉêÇë] ¹¤²Ä¿ÚÇàÄê»ù½ð´ó¸ÅʲôÑùÄÜÉϻ᣿ +15 ½ñÍíÍƼö22 2024-06-20 21/1050 2024-06-22 23:04 by qbn0326
[Óлú½»Á÷] Óлú·´Ó¦ 50+3 ÓêÖеĺìõ¹å 2024-06-19 6/300 2024-06-22 00:10 by ϲ»¶ºÍÒ»Ñõ»¯¶þÌ
[»ù½ðÉêÇë] ½ÌÓý²¿»ù½ð +5 m1393 2024-06-21 5/250 2024-06-21 21:13 by odes
[ÂÛÎÄͶ¸å] ACS AMI ·µ»ØÉó¸åÒâ¼û£¬Ò»¸ö´óÐÞ£¬Á½¸ö¾Ý¸å£¬±à¼­¸øµÄÐÞ¸ÄÖØͶ +7 ÖÇÉÌÒѸüР2024-06-19 7/350 2024-06-20 19:54 by kinlin13
[ÂÛÎÄͶ¸å] Ͷ¸åÇóÖú 6+3 С¶ÌÍÈ°²ç÷À­ 2024-06-19 4/200 2024-06-20 17:40 by ²»Ò»ÑùÑÌ»ð12345
[»ù½ðÉêÇë] ÃæÇàµØ»áÆÀʱ¼ä£¿£¿£¿ +7 Axvdvbfs 2024-06-19 8/400 2024-06-20 11:16 by ·ң»¹ÓÐË­
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û